At a glance
- Originator Merck & Co
- Developer Takeda
- Class Antiasthmatics
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 12 Jun 2000 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 29 Mar 1996 Preclinical development for Thrombosis in Japan (Unknown route)